The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis : A summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council
DISCLOSURES: Funding for this summary was contributed by Blue Cross Blue Shield of MA, California Healthcare Foundation, The Patrick and Catherine Weldon Donaghue Medical Research Foundation, Arnold Ventures, and Kaiser Foundation Health Plan Inc., to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, America's Health Insurance Plans, AbbVie, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer Ingelheim, Cambia Health Services, CVS, Editas, Evolve Pharmacy Solutions, Express Scripts, Genentech/ Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, Health First, Health Partners, Humana, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer. Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, Sun Life Financial, uniQure, and United Healthcare. Mr Nikitin, Ms McKenna, Ms Richardson, and Drs Rind and Pearson are employed by ICER. Through their affiliated institutions, Drs Makam, Carlson, and Suh received funding from ICER for the work described in this summary.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Journal of managed care & specialty pharmacy - 29(2023), 2 vom: 31. Feb., Seite 216-221 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nikitin, Dmitriy [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Edaravone |
|---|
| Anmerkungen: |
Date Completed 31.01.2023 Date Revised 01.08.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.18553/jmcp.2023.29.2.216 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352157550 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352157550 | ||
| 003 | DE-627 | ||
| 005 | 20231226053056.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18553/jmcp.2023.29.2.216 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1173.xml |
| 035 | |a (DE-627)NLM352157550 | ||
| 035 | |a (NLM)36705279 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nikitin, Dmitriy |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis |b A summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.01.2023 | ||
| 500 | |a Date Revised 01.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a DISCLOSURES: Funding for this summary was contributed by Blue Cross Blue Shield of MA, California Healthcare Foundation, The Patrick and Catherine Weldon Donaghue Medical Research Foundation, Arnold Ventures, and Kaiser Foundation Health Plan Inc., to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from Aetna, America's Health Insurance Plans, AbbVie, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer Ingelheim, Cambia Health Services, CVS, Editas, Evolve Pharmacy Solutions, Express Scripts, Genentech/ Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, Health First, Health Partners, Humana, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer. Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, Sun Life Financial, uniQure, and United Healthcare. Mr Nikitin, Ms McKenna, Ms Richardson, and Drs Rind and Pearson are employed by ICER. Through their affiliated institutions, Drs Makam, Carlson, and Suh received funding from ICER for the work described in this summary | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Edaravone |2 NLM | |
| 650 | 7 | |a S798V6YJRP |2 NLM | |
| 650 | 7 | |a sodium phenylbutyrate and taurursodiol |2 NLM | |
| 700 | 1 | |a Makam, Anil N |e verfasserin |4 aut | |
| 700 | 1 | |a Suh, Kangho |e verfasserin |4 aut | |
| 700 | 1 | |a McKenna, Avery |e verfasserin |4 aut | |
| 700 | 1 | |a Carlson, Josh J |e verfasserin |4 aut | |
| 700 | 1 | |a Richardson, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Rind, David M |e verfasserin |4 aut | |
| 700 | 1 | |a Pearson, Steven D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of managed care & specialty pharmacy |d 2014 |g 29(2023), 2 vom: 31. Feb., Seite 216-221 |w (DE-627)NLM235806323 |x 2376-1032 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2023 |g number:2 |g day:31 |g month:02 |g pages:216-221 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18553/jmcp.2023.29.2.216 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2023 |e 2 |b 31 |c 02 |h 216-221 | ||